OakChart

Pulsenmore Ltd

PLSMHealthcare·Medical Devices·Israel·Nano·NASD·Nov 11 • 2:18 PM ET

1.46-0.04 (-2.67%)
2026-11-11 20:20 CET
Market cap
12.03 USD m
Revenue, TTM
12.89 USD m
Net income, TTM
-9.35 USD m
Free cash flow, TTM
-10.28 USD m
EPS diluted, TTM
-1.44
P/E
-
Compare

Price

PLSM against its 20 and 50-day averages
2050
5.0010.0029.2M58.3MMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26PLSMclose 1.4620-day 1.6750-day 2.051.4652w high

88.7% under the 52-week high of 12.97 on 24 Jun 2026. 52-week low 1.42 on 6 Nov 2026. Last 15 sessions, 33.8% high to low

Profile

PLSM
52-week range, 0% of the way up
1.4212.97

Pulsenmore Ltd. engages in research and development, production, marketing, and sale of self-scan ultrasound devices for remote clinical diagnosis and screening. It also offers a mobile app that guides the patient through a self-scan and enables online consolation with a clinician; as well as a clinician dashboard that allows clinicians to review scans and interacts with the patient remotely. The company was founded by Elazar Sonnenschein on October 27, 2014 and is headquartered in Omer, Israel.

Employees63
IPOJan 21, 2026
ATR, 14d0.17
Rel volume0.31
Short float0.15%
Insider own41.37%
Inst own5.99%

Snapshot

6 groups

Valuation

Index-
Market Cap11.71M
Enterprise Value-0.18M
Income-9.35M
Sales12.89M
Book/sh2.49
Cash/sh2.92
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees63
IPOJan 21, 2026

Ratios

P/E-
Forward P/E-
PEG-
P/S0.91
P/B0.59
P/C0.50
P/FCF-
EV/EBITDA-
EV/Sales-0.01
Quick Ratio1.69
Current Ratio1.84
Debt/Eq0.71
LT Debt/Eq0.01
Option/ShortNo / Yes

Earnings

EPS (ttm)-1.44
EPS next Y-
EPS next Q-
EPS this Y-
EPS next Y-
EPS next 5Y-
EPS past 3/5Y13.21% -1.94%
Sales past 3/5Y14.32% -
EPS Y/Y TTM24.28%
Sales Y/Y TTM406.71%
EPS Q/Q-77.35%
Sales Q/Q80.08%
EarningsAug 31 BMO
EPS/Sales Surpr.- -

Ownership

Insider Own41.37%
Insider Trans0.28%
Inst Own5.99%
Inst Trans1.49%
ROA-26.98%
ROE-48.74%
ROIC-57.23%
Gross Margin81.24%
Oper. Margin-33.20%
Profit Margin-72.48%
SMA20-12.83%
SMA50-28.66%
SMA200-59.86%
Trades-

Technical

Shs Outstand6.50M
Shs Float4.70M
Short Float0.15%
Short Ratio0.12
Short Interest0.01M
52W High12.97 -88.74%
52W Low1.42 2.80%
Volatility9.14% 9.63%
ATR (14)0.17
RSI (14)29.08
Beta-
Rel Volume0.31
Avg Volume59.00K
Volume13,632

Performance

Perf Week-7.01%
Perf Month-23.16%
Perf Quarter-51.66%
Perf Half Y-68.40%
Perf YTD-84.55%
Perf Year-
Perf 3Y-
Perf 5Y-
Perf 10Y-
Recom-
Target Price-
Prev Close1.50
Price1.46
Change %-2.67%

Peers

Mkt cap
TickerCompanyMkt cap
BFLYButterfly Network Inc1.86B
NNOXNano X Imaging Ltd28.99M
HSCSHeartSciences Inc11.73M
IVFINVO Fertility Inc3.03M
IRTCiRhythm Holdings Inc2.95B
DRIODarioHealth Corp22.24M
IRIXIRIDEX Corp12.78M
MODDModular Medical Inc17.19M
CTSOCytosorbents Corp17.84M
SINTSINTX Technologies Inc11.79M

Insider trading

2 filings
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Sonnenschein ElazarChief Executive OfficerNov 04 '26Buy1.709,25915,740892,421Nov 05 04:15 PM
Guz-Lavi RacheliDirectorOct 14 '26Option Exercise0.0346,8741,50046,874Oct 14 04:15 PM

News

latest 14 of 38
  • Pulsenmore Strengthens U.S. Commercial Leadership, Appoints Med-Tech Veteran David Woods as Chief Commercial Officer (PR Newswire)
  • Pulsenmore Expands Its Fertility Platform into the UK (PR Newswire)
  • Pulsenmore Expands into Fertility Care: Completes CE European Registration of Home Ultrasound System for Follicular Monitoring (PR Newswire)
  • Pulsenmore Ltd. Announces Financial Results and Business Highlights for the First Half of 2026 (PR Newswire)
  • Pulsenmore Ltd. To Announce Financial Results and Business Highlights and Hold Conference Call for the First Half of 2026 (PR Newswire) -5.10%
  • Pulsenmore Expands Its Home Ultrasound Activity in Israel: Ichilov Adopts the Technology, Expanding Access to At-Home Pregnancy Monitoring (PR Newswire)
  • Pulsenmore Receives Second AI Grant Within One Month: Israel Innovation Authority Approves $1.27 Million for SmartScan AI Program (PR Newswire)
  • Pulsenmore Shares Soar After Joining Israel's Healthcare AI Sandbox Programme (PLSM) (Investors Hub) -6.22%
  • Pulsenmore Selected for Israel Innovation Authority and Ministry of Health Program to Lead an $1 Million AI Development Project (PR Newswire)
  • Pulsenmore Announces Pricing of $7.5 Million Private Placement with a Single Healthcare Focused Institutional Investor (PR Newswire) -10.47%
  • Why Did PLSM Stock Surge More Than 200% Today? (Stocktwits) +93.26%
  • Pulsenmore Announces Strategic Partnership with Ouma Health to Expand Access to Remote Prenatal Care Across the United States (PR Newswire)
  • Pulsenmore Announces Full Year 2025 Financial Results and Webcast (PR Newswire)
  • Pulsenmore Announces Full Year 2025 Earnings Conference Call (PR Newswire) -5.51%

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
No quarterly earnings.

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
No annual earnings.

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
No estimate revisions.

Estimate history

EPS, annual-0.2-0.648-1.547-1.091-2.48-1.55-0.713
Period2019202020212022202320242025
EPS, quarterly
Period
Sales, annual000.4893.2191.6782.614.808
Period2019202020212022202320242025
Sales, quarterly
Period
Shares, annual6.1656.1655.7836.246.2526.2726.503
Period2019202020212022202320242025
Shares, quarterly
Period

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY
Total Revenue12.894.812.611.683.220.490.000.00
Cost of Goods Sold Incl. D&A2.422.572.051.672.040.420.100.06
Gross Profit10.482.240.560.011.180.06-0.10-0.06
Selling, General and Administrative Excl. Other14.7612.5611.9615.0814.936.863.761.05
Research and Development5.604.695.118.228.593.292.990.73
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-4.28-10.32-11.40-15.07-13.75-6.79-3.86-1.11
Interest Expense6.000.120.150.170.100.090.030.02
Unusual Expense0.00-6.800.004.23-3.13-0.23-0.02-0.01
Net Income Before Taxes-9.35-4.60-9.94-15.85-6.58-7.93-3.99-1.23
Income Taxes0.000.00-0.020.030.000.000.000.00
Consolidated Net Income-9.35-4.60-9.92-15.88-6.58-7.93-3.99-1.23
Net Income From Continuing Operations-9.35-4.60-9.92-15.88-6.58-7.93-3.99-1.23
Net Income-9.35-4.60-9.92-15.88-6.58-7.93-3.99-1.23
EPS (Recurring)-1.44-1.45-1.55-2.02-1.45-1.58-0.65-0.20
EPS (Basic, Before Extraordinaries)-1.44-0.71-1.55-2.48-1.09-1.55-0.65-0.20
EPS (Diluted)-1.44-0.71-1.55-2.48-1.09-1.55-0.65-0.20
EBITDA-3.37-9.51-10.63-14.42-13.37-6.62-3.76-1.05
Non-Operating Income (Expense)0.94-0.951.613.624.14-1.28-0.13-0.11
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense0.120.150.402.181.520.890.200.00
Price To Sales Ratio2.918.7827.0259.3534.05376.89--
Gross Margin81.2446.6221.430.6536.5513.12--
Operating Margin-33.20-214.69-436.96-898.29-427.24-1,390.24--
Net Margin-72.48-95.59-380.25-946.46-204.54-1,623.89--
Shares Outstanding6.506.506.276.256.245.786.176.17
Market Capitalization12.0312.03------

Income statement, quarterly

Currency USD, millions
Metric2026S12025S22025S12024S22024S12023S22023S12022S2
Total Revenue2.0010.891.111.431.180.990.682.17
Cost of Goods Sold Incl. D&A1.271.150.710.890.760.680.401.07
Gross Profit0.739.740.410.550.420.320.281.10
Selling, General and Administrative Excl. Other7.577.196.146.525.857.358.359.07
Research and Development2.792.822.232.772.663.644.915.56
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-6.842.56-5.74-5.98-5.43-7.03-8.08-7.97
Interest Expense5.260.741.330.000.193.970.33-
Unusual Expense0.000.000.000.000.000.000.000.00
Net Income Before Taxes-11.552.21-6.44-5.65-4.29-9.54-6.22-5.52
Income Taxes0.000.000.00-0.030.010.010.020.00
Consolidated Net Income-11.552.21-6.44-5.62-4.30-9.56-6.24-5.52
Net Income From Continuing Operations-11.552.21-6.44-5.62-4.30-9.56-6.24-5.52
Net Income-11.552.21-6.44-5.62-4.30-9.56-6.24-5.52
EPS (Recurring)-1.780.34-1.00-0.90-0.69-1.53-1.00-0.89
EPS (Basic, Before Extraordinaries)-1.780.34-1.00-0.90-0.69-1.53-1.00-0.89
EPS (Diluted)-1.780.34-1.00-0.90-0.69-1.53-1.00-0.89
EBITDA-6.342.97-5.34-5.58-5.05-6.63-7.82-7.75
Non-Operating Income (Expense)0.540.390.620.331.321.462.182.45
Stock Option Compensation Expense0.080.040.110.250.150.390.390.69
Price To Sales Ratio2.913.5513.3426.4620.3558.2130.1135.53
Gross Margin36.6089.4536.4338.0535.7732.0441.0350.73
Operating Margin-341.4023.48-515.65-417.34-460.92-707.03-1,194.07-368.15
Net Margin-576.8420.27-579.07-392.39-365.43-961.71-922.88-255.03
Shares Outstanding6.506.506.316.276.266.256.256.24
Market Capitalization12.0341.29------

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY
Cash & Short Term Investments21.7428.5939.4051.9549.311.911.34
Short Term Receivables1.531.260.583.221.710.090.13
Inventories2.156.416.644.792.110.580.00
Other Current Assets0.120.08----0.00
Total Current Assets25.5436.3446.6259.9753.132.581.47
Net Property, Plant & Equipment2.232.593.342.580.580.230.27
Total Investments and Advances0.000.000.004.420.000.000.00
Intangible Assets-0.000.000.000.000.000.00
Other Assets4.180.000.000.000.000.000.00
Total Assets31.9638.9249.9666.9753.712.811.74
Short Term Debt Incl. Current Port. of LT Debt0.320.270.260.240.180.030.07
Accounts Payable0.620.651.371.660.270.210.08
Other Current Liabilities2.302.992.382.501.710.660.13
Total Current Liabilities3.243.914.004.412.160.890.28
Long Term Debt0.170.310.670.880.070.270.37
Provision for Risks Charges0.000.000.000.000.000.000.00
Other Liabilities0.006.336.786.800.260.000.00
Total Liabilities3.4110.5511.4512.092.501.160.65
Non-Equity Reserves2.471.781.791.741.820.740.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.00
Common Equity26.0726.5936.7253.1449.390.901.09
Total Shareholders Equity26.0726.5936.7253.1449.390.901.09
Accumulated Minority Interest0.000.000.000.000.000.000.00
Total Equity26.0726.5936.7253.1449.390.901.09
Total Liabilities & Stockholders Equity31.9638.9249.9666.9753.712.811.74
Book Value Per Share4.014.245.878.528.540.150.18
Tangible Book Value Per Share4.014.245.878.528.540.150.18
Full-Time Employees63637675563421
Price to Book Ratio0.60------
Return on Assets-12.97-22.33-27.16-10.91-28.08-175.92-
Return on Equity-17.46-31.35-35.34-12.84-31.55-402.29-
Return on Invested Capital-17.52-36.90-42.47-12.19-16.04-341.37-84.71
Quick Ratio7.227.659.9912.5223.672.235.27
Current Ratio7.889.2811.6513.6124.642.885.27

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY
Net Income-9.91-4.60-9.92-15.88-6.58-7.93-3.99-1.23
Depreciation0.950.810.770.650.390.170.110.07
Other Funds (Non Cash)6.152.200.983.51-4.131.810.330.11
Funds from Operations-2.80-1.58-8.17-11.71-10.33-5.95-3.56-1.05
Extraordinary Item0.000.000.000.000.000.000.000.00
Changes in Working Capital-7.42-6.97-0.960.112.88-2.110.800.03
Cash from Operating Activities-10.22-8.56-9.13-11.61-7.45-8.06-2.75-1.02
Capital Expenditures-0.06-0.04-0.14-1.06-1.34-0.24-0.11-0.05
Net Assets From Acquisitions0.000.000.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.000.000.00
Purchase or Sale of Investments10.183.0813.8914.58-89.12-12.530.000.00
Purchase of Investments0.640.000.000.00-89.12-12.530.000.00
Sale Or Maturity of Investments9.553.0813.8914.580.000.000.000.00
Other Uses0.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.00
Cash from Investing Activities10.123.0413.7513.52-90.46-12.77-0.11-0.05
Cash Dividends Paid0.000.000.000.000.000.000.000.00
Change in Capital Stock0.010.010.000.0015.2354.003.552.43
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.00
Sale of Common Pref Stock0.010.010.000.0015.2354.003.552.43
Proceedsfrom Stock Options0.000.000.000.0015.2354.003.552.43
Issuance or Reduction of Debt, Net6.840.000.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.000.000.00
Reduction of Long Term Debt-0.000.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.060.38-0.030.050.321.410.000.00
Other Financing Activities Uses-0.09-0.12-0.03-0.08-0.040.000.000.00
Cash from Financing Activities6.450.00-0.42-0.3115.1755.243.452.37
Exchange Rate Effect-0.38-0.160.470.711.08-1.33-0.14-0.10
Net Change in Cash5.98-5.674.672.31-81.6633.090.441.20
Free Cash Flow-10.28-8.59-9.27-12.67-8.79-8.30-2.86-1.07
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.00
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026S12025S22025S12024S22024S12023S2
Cash & Short Term Investments23.4221.7425.7428.5932.0639.40
Short Term Receivables1.411.531.171.261.180.58
Inventories2.132.156.426.416.796.64
Other Current Assets-0.12-0.08--
Total Current Assets26.9625.5433.3336.3440.0346.62
Net Property, Plant & Equipment1.962.232.402.592.903.34
Total Investments and Advances0.000.000.000.000.000.00
Intangible Assets--0.000.000.000.00
Other Assets4.614.180.000.000.000.00
Total Assets33.5331.9635.7338.9242.9349.96
Short Term Debt Incl. Current Port. of LT Debt11.420.320.270.270.260.26
Accounts Payable1.160.620.640.650.351.37
Other Current Liabilities2.072.303.272.992.512.38
Total Current Liabilities14.663.244.183.913.124.00
Long Term Debt0.110.170.210.310.530.67
Other Liabilities0.000.006.806.336.506.78
Total Liabilities14.773.4111.1910.5510.1411.45
Non-Equity Reserves2.542.472.421.781.711.79
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity16.2226.0722.1326.5931.0736.72
Total Shareholders Equity16.2226.0722.1326.5931.0736.72
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity16.2226.0722.1326.5931.0736.72
Total Liabilities & Stockholders Equity33.5331.9635.7338.9242.9349.96
Book Value Per Share2.494.013.514.244.965.87
Tangible Book Value Per Share2.494.013.514.244.965.87
Price to Book Ratio0.601.58----
Return on Assets-26.98-11.94-30.67-22.33-27.39-27.02
Return on Equity-48.74-16.07-45.35-31.34-36.45-35.16
Return on Invested Capital-70.758.42-28.83-20.90-13.61-25.56
Quick Ratio1.697.226.447.6510.659.99
Current Ratio1.847.887.989.2812.8211.65

Cash flow, quarterly

Currency USD, millions
Metric2026S12025S22025S12024S22024S12023S2
Net Income-11.551.65-6.44-5.61-4.30-9.25
Depreciation0.500.450.400.400.370.38
Other Funds (Non Cash)5.190.961.340.670.312.44
Funds from Operations-5.863.05-4.70-4.54-3.62-6.42
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital0.50-7.910.640.94-1.90-0.39
Cash from Operating Activities-5.36-4.86-4.06-3.59-5.52-6.81
Capital Expenditures-0.04-0.01-0.03-0.09-0.050.07
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments6.343.85-0.6410.273.60-12.56
Purchase of Investments0.000.64-0.640.000.000.00
Sale Or Maturity of Investments6.343.210.0010.273.60-12.56
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities6.293.83-0.6610.183.55-12.49
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock0.000.010.000.000.000.00
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock0.000.010.000.000.000.00
Proceedsfrom Stock Options0.000.000.000.000.000.00
Issuance or Reduction of Debt, Net6.840.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.00--0.000.000.00
Net Financing Active Other Cash Flow-0.050.110.290.00-0.030.04
Other Financing Activities Uses-0.05-0.04-0.080.00-0.03-0.02
Cash from Financing Activities6.56-0.100.10-0.20-0.23-0.13
Exchange Rate Effect-0.24-0.13-0.030.190.28-0.97
Net Change in Cash7.24-1.26-4.656.58-1.91-20.40
Free Cash Flow-5.41-4.87-4.09-3.68-5.57-6.74

Revenue breakdown

Surgical & Medical Instruments & Apparatus2024: 2.61M 2025: 11.61M
Israel2024: 2.61M 2025: 11.61M

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-300.15%0.0M4.7M60.04K
2026-10-150.06%0.0M4.7M68.89K
2026-09-300.20%0.0M3.9M474.30K
2026-09-150.55%0.0M3.9M1.44M
2026-08-310.39%0.0M3.9M1.39M
2026-08-140.23%0.0M3.9M1.41M
2026-07-310.43%0.0M3.9M1.48M
2026-07-158.35%0.3M3.9M1.52M
2026-06-301.63%0.1M3.9M1.05M
2026-06-150.11%0.0M3.9M19.47K
2026-05-290.07%0.0M3.9M19.41K
2026-05-150.72%0.0M3.9M16.92K
2026-04-300.03%0.0M3.5M6.72K
2026-04-150.02%0.0M3.5M9.81K
2026-03-310.01%0.0M5.9M10.83K
2026-03-130.02%0.0M5.9M10.69K
2026-02-270.03%0.0M5.9M12.18K
2026-02-130.01%0.0M5.9M15.54K
2026-01-300.05%0.0M5.9M26.50K

Option chain

expiry 2026-11-11
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
No option chain for this symbol.

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-054Statement of changes in beneficial ownership of securities2026-11-04SEC
2026-10-214Statement of changes in beneficial ownership of securities2026-10-19SEC
2026-10-144Statement of changes in beneficial ownership of securities2026-10-14SEC
2026-10-143Initial statement of beneficial ownership of securities2026-10-06SEC
2026-10-136-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-10-13SEC
2026-10-08SCHEDULE 13GSEC
2026-09-176-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-09-17SEC
2026-09-086-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-09-08SEC
2026-09-01EFFECTEffectiveness filing by commission orderSEC
2026-08-31POS AMPost-effective amendment to a registration statement that is not immediately effective upon filingSEC
2026-08-31S-8Initial registration statement for securities to be offered to employees pursuant to employee benefit plansSEC
2026-08-316-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-06-30SEC
2026-08-196-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-08-19SEC
2026-08-176-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-08-17SEC
2026-08-066-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-08-06SEC
2026-07-13424B3SEC
2026-07-136-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-07-13SEC
2026-07-10EFFECTEffectiveness filing by commission orderSEC
2026-07-07DNotice of sales of securities on Form D (Regulation D)SEC
2026-07-02F-1Registration statement for certain foreign private issuersSEC
2026-07-016-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-07-01SEC
2026-07-016-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-07-01SEC
2026-06-256-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-06-25SEC
2026-06-246-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-06-24SEC
2026-06-126-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-06-12SEC
2026-05-076-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-05-07SEC
2026-04-28SCHEDULE 13GSEC
2026-03-306-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-03-30SEC
2026-03-3020-FRegistration statement under Section 12 of the Securities Exchange Act of 1934 or an annual or transition report filed under Section 13(a) or 15(d) of the Exchange Act for a foreign private issuer.2025-12-31SEC
2026-03-183Initial statement of beneficial ownership of securities2026-03-18SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-1115.74K100
2026-100000
2026-090000
2026-080000
2026-070000
2026-060000
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
Aquamarine Financial5.21%
UBS Group AG0.20%
MCGUIRE CAPITAL ADVISORS INC0.01%
BARCLAYS PLC0.01%
Cornerstone Financial Management LLC0.00%

Funds

Fund% owned
-

OakChart. PLSM. Cached 15 minutes.

Some panels did not load: ratings.